Cancer Network’s FACE-OFF introduces the evolving role of cereblon E3 ligase modulators, or CELMoDs, in relapsed/refractory multiple myeloma.
FACE-OFF: CELMoDs in Relapsed/Refractory Multiple Myeloma Evaluating the Role of Cereblon E3 Ligase Modulators in Patient Selection, Sequencing, and Practical Management
Dr. Joshua Richter reviews the EXCALIBER-RRMM study evaluating iberdomide in combination with daratumumab and dexamethasone in patients with relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
2
BCMA/GPRC5D CAR T-Cell Therapy Shows Early Efficacy in R/R Multiple Myeloma
3
Integrating Talazoparib Plus Enzalutamide Into HRR-Mutated mHSPC Care
4
Proton Therapy Does Not Improve Survival in Hepatocellular Carcinoma
5